Cargando…

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes

BACKGROUND: Glucocorticoid drugs are highly effective anti-inflammatory agents, but chronic use is associated with extensive pharmacodynamic safety concerns that have a considerable negative impact on patient quality of life. PURPOSE: Vamorolone (VBP15) is a first-in-class steroidal multi-functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffman, Eric P., Riddle, Valerie, Siegler, Maxime A., Dickerson, Daniel, Backonja, Miroslav, Kramer, William G., Nagaraju, Kanneboyina, Gordish-Dressman, Heather, Damsker, Jesse M., McCall, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136660/ https://www.ncbi.nlm.nih.gov/pubmed/29524454 http://dx.doi.org/10.1016/j.steroids.2018.02.010

Ejemplares similares

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone
por: Fiorillo, Alyson A., et al.
Publicado: (2018)

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy
por: Heier, Christopher R, et al.
Publicado: (2019)

Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor
por: Wells, Elizabeth, et al.
Publicado: (2016)

The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice
por: Almeida, Luis E. F., et al.
Publicado: (2018)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects
por: Heier, Christopher R, et al.
Publicado: (2013)

Glucocorticoid-Treated Mice Are an Inappropriate Positive Control for Long-Term Preclinical Studies in the mdx Mouse
por: Sali, Arpana, et al.
Publicado: (2012)

Characterization of Dysferlin Deficient SJL/J Mice to Assess Preclinical Drug Efficacy: Fasudil Exacerbates Muscle Disease Phenotype
por: Rayavarapu, Sree, et al.
Publicado: (2010)

Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
por: Tatem, Kathleen S., et al.
Publicado: (2014)

Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
por: Ziemba, Michael, et al.
Publicado: (2021)

Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy
por: Grounds, Miranda D., et al.
Publicado: (2023)

Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease
por: Heier, Christopher R, et al.
Publicado: (2016)

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children
por: Hathout, Yetrib, et al.
Publicado: (2016)

Evaluation of Skeletal and Cardiac Muscle Function after Chronic Administration of Thymosin β-4 in the Dystrophin Deficient Mouse
por: Spurney, Christopher F., et al.
Publicado: (2010)

VBP15, a Glucocorticoid Analogue, Is Effective at Reducing Allergic Lung Inflammation in Mice
por: Damsker, Jesse M., et al.
Publicado: (2013)

The Proton Pump Inhibitor Lansoprazole Improves the Skeletal Phenotype in Dystrophin Deficient mdx Mice
por: Sali, Arpana, et al.
Publicado: (2013)

Non-Invasive MRI and Spectroscopy of mdx Mice Reveal Temporal Changes in Dystrophic Muscle Imaging and in Energy Deficits
por: Heier, Christopher R., et al.
Publicado: (2014)

Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
por: Elhalag, Rowan H., et al.
Publicado: (2023)

Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
por: Guglieri, Michela, et al.
Publicado: (2022)

Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia
por: Duddy, William, et al.
Publicado: (2015)

Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice
por: McCormack, Nikki M., et al.
Publicado: (2023)

Omigapil Treatment Decreases Fibrosis and Improves Respiratory Rate in dy(2J) Mouse Model of Congenital Muscular Dystrophy
por: Yu, Qing, et al.
Publicado: (2013)

Proteomic profiling of glucocorticoid-exposed myogenic cells: Time series assessment of protein translocation and transcription of inactive mRNAs
por: Reeves, Erica KM, et al.
Publicado: (2009)

The Role of Bridging Therapy in Hepatocellular Carcinoma
por: Galuppo, Roberto, et al.
Publicado: (2013)

Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit
por: Sreetama, Sen Chandra, et al.
Publicado: (2018)

Death and Disability Reported with Cases of Vaccine Anaphylaxis Stratified by Administration Setting: An Analysis of the Vaccine Adverse Event Reporting System from 2017 to 2022
por: Klosko, Rachel C., et al.
Publicado: (2023)

Effect of TNF-α on human ARPE-19-secreted proteins
por: An, Eunkyung, et al.
Publicado: (2008)

Effect of endurance exercise on microRNAs in myositis skeletal muscle—A randomized controlled study
por: Boehler, Jessica F., et al.
Publicado: (2017)

OPN‐a induces muscle inflammation by increasing recruitment and activation of pro‐inflammatory macrophages
por: Many, Gina M., et al.
Publicado: (2016)

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017)

Metabolic remodeling agents show beneficial effects in the dystrophin-deficient mdx mouse model
por: Jahnke, Vanessa E, et al.
Publicado: (2012)

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis
por: Conklin, Laurie S., et al.
Publicado: (2018)

NKG2A inhibits TH2 cell effector function in vitro
por: Freishtat, Robert J, et al.
Publicado: (2007)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Correction: Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the Dystrophin Deficient mdx mice
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Functional and Molecular Effects of Arginine Butyrate and Prednisone on Muscle and Heart in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Guerron, Alfredo D., et al.
Publicado: (2010)

Role of non-immune mechanisms of muscle damage in idiopathic inflammatory myopathies
por: Coley, William, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_c6qsoesld1ecj7u7j0q1ci2i5h